Food Hypersensitivity Clinical Trial
— TRACEextensionOfficial title:
Mechanisms Underlying the Change in Threshold or Severity of Peanut-allergic Reactions in TRACE Peanut Study Participants - Extension Study
Verified date | October 2019 |
Source | Imperial College London |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Food allergy affects up to 10% of the population. The mainstay of management involves dietary
avoidance and provision of rescue medication in the event of an accidental reaction. The
Integrated approaches to food allergen and allergy management (iFAAM) collaboration is an
EU-funded academic/clinical/industry consortium with the aim to improve allergen risk
management including food labelling. Much of this work requires the validation of the minimum
'eliciting dose' for the food-allergic population and how this can be translated into risk
management.
A number of studies (including iFAAM and the TRACE study - NCT01429896) have assessed the
eliciting dose for peanut allergic patients, using food challenges where peanut-allergic
individuals are eat incremental doses of peanut under strict medical supervision.
In this extension study, peanut-allergic subjects will have undergone (in a cross-over
manner) three double-blind, placebo-controlled food challenges to peanut:
1. incremental doses of peanut in a water-continuous matrix;
2. incremental doses of peanut baked into a cookie biscuit;
3. a single dose of peanut in a water-continuous matrix.
The differences in eliciting dose, symptom pattern and underlying physiological mechanisms
will provide essential data on how the presentation and consumption of peanut affects the
amount needed to trigger an allergic reaction, to inform industry and food regulators as to
how to best protect the food-allergic population.
Status | Completed |
Enrollment | 17 |
Est. completion date | May 19, 2017 |
Est. primary completion date | May 19, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: - Written informed consent. - Male and female participants in the TRACE study (NCT01429896) who are 18-45 years of age at the time of entry to the TRACE study (Visit 1) and had a positive DBPCFC to peanut at baseline (Visit 1). Exclusion criteria - unable to comply with study procedures |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Imperial College London | Cambridge University Hospitals NHS Foundation Trust, Food Standards Agency, United Kingdom, University of Manchester |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Minimum eliciting dose | Minimum eliciting dose of peanut to trigger an objective allergic reaction according to international consensus criteria (PRACTALL)) | 2 hours | |
Secondary | Symptom pattern | Symptoms experienced following peanut challenge (defined according to international consensus criteria (PRACTALL) ) | 12 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01904604 -
Peanut Epicutaneous Phase II Immunotherapy Clinical Trial
|
Phase 2 | |
Enrolling by invitation |
NCT04885959 -
The Effects of Traditional Asian Diet on Gut Microbiome and Metabolome in Healthy Volunteers and Pregnancy on Subsequent Infant's Allergy Development
|
N/A | |
Recruiting |
NCT03974555 -
Epidemiological Investigation and Cohort Study on Food Allergy in Children Aged 3 to 6 Years in Wenzhou and Taizhou Urban Areas
|
||
Recruiting |
NCT05177744 -
Toxicity of Micro and Nano Plastics Combined With Environmental Contaminants on the Risk of Allergic Disease
|
||
Completed |
NCT01420705 -
Bacille Calmette-Guérin (BCG) Vaccine and Atopy
|
N/A | |
Completed |
NCT00850668 -
Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults
|
Phase 1 | |
Withdrawn |
NCT00736112 -
Food Allergy - Tubes - Adenoids (FATA) Trial
|
N/A | |
Active, not recruiting |
NCT00298337 -
Use of Probiotic Bacteria in Prevention of Allergic Disease in Children 1999-2008
|
Phase 2/Phase 3 | |
Completed |
NCT03693456 -
Food Allergy Diagnostic Test Response to Previous Oral Challenge Response
|
N/A | |
Completed |
NCT00461097 -
Oral Immunotherapy for Childhood Egg Allergy
|
Phase 2 | |
Completed |
NCT02606721 -
Food Allergy Challenge Diagnostic Study
|
||
Active, not recruiting |
NCT02457416 -
Take Away Food Allergy; Inducing Tolerance in Children Allergic to Peanut
|
N/A | |
Completed |
NCT02825069 -
Study on the Induction of Food Tolerance in Babies
|
N/A | |
Completed |
NCT02350660 -
Oral Immunotherapy for Peanut and Mammalian Meat Allergies
|
N/A | |
Completed |
NCT01084174 -
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy
|
Phase 1/Phase 2 | |
Completed |
NCT00597675 -
Oral Immunotherapy for Peanut Allergy (PMIT)
|
Phase 2 | |
Completed |
NCT00932828 -
Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study
|
Phase 2 | |
Completed |
NCT01373242 -
Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance
|
Phase 1/Phase 2 | |
Completed |
NCT00578656 -
An Interventional Study of Milk Allergy
|
Phase 0 | |
Completed |
NCT00356174 -
An Observational Study of Childhood Food Allergy
|
N/A |